摘要
目的:探讨Guidezilla^(TM)导管在冠状动脉慢性完全闭塞病变接受经桡动脉介入治疗的应用效果及安全性。方法:选取2016年1-12月本院心内科接受治疗的11例慢性完全闭塞病变接受经桡动脉介入治疗的患者进行研究,所有患者均给予经桡动脉入径介入治疗手术,术中常规应用6F指引导管,术中对导引导丝无法通过球囊或支架的情况均应用Guidezilla^(TM)延长导管。术后对患者随访6个月,记录主要不良心脏事件发生情况、手术成功率及术中并发症发生情况。结果:11例患者应用Guidezilla^(TM)延长导管,支架均可达到靶病变处,所有患者介入治疗均取得成功。随访期内,无患者发生急性心肌梗死、死亡、靶血管再次血运重建等事件;1例患者在应用Guidezilla^(TM)延长导管时发生心绞痛,1例出现导管嵌顿,及时进行处于和对症治疗后好转;无患者出现导丝所致冠脉穿孔和心脏压塞、急性支架内血栓等并发症。结论:对冠状动脉慢性完全闭塞病变者行介入治疗时,当指引导管难以通过球囊或支架到达靶病变区时,Guidezilla^(TM)延长导管可有效增强导管系统的支撑力,进而提高手术成功率,降低术后并发症发生率,值得临床推广应用。
Objective:To investigate the effect and safety of Guidezilla guide extension catheter treatment application in chronic total occlusion(CTO)treated by percutaneous coronary intervention(PCI).Method:A total of 11 cases of CTO patients in our hospital from January 2016 to December 2016 were given PCI,6F guiding catheter were routine used in surgery,Guidezilla guide extension catheter were used to solve the problem of the guide wire not passing through the balloon or stent.Major adverse cardiac events,the success rate of surgery and intraoperative incidence were recorded in postoperative patients for 6 months.Results:All patients were successfully completed interventional therapies.During the follow-up period,no patient had acute myocardial infarction,death,target vessel revascularization events;1 patient in the application of Guidezilla guide extension catheter was occurred angina pectoris,1 patient was occurred catheter incarceration,the symptoms were improved after symptomatic treatment;no patients were occurred complication caused by guidewire.Conclusion: When CTO patients are treated by PCI,the guiding pipe is difficult to reach the target by balloon or stent lesion area,Guidezilla guide extension catheter can effectively enhance the supporting force of the catheter system,improve the success rate of surgery,and reduce the incidence of postoperative complications,it is worthy of clinical application.
作者
刘芳
杨兆瑞
丁春平
LIU Fang;YANG Zhaorui;DING Chunping(Yichun People’s Hospital,Yichun 336000,Chin)
出处
《中国医学创新》
CAS
2018年第10期102-105,共4页
Medical Innovation of China
基金
宜春市科技局重点计划课题(JXYC2017KSA005)